Analysts expect Wave Life Sciences Ltd (NASDAQ:WVE) to report ($1.19) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Five analysts have provided estimates for Wave Life Sciences’ earnings, with estimates ranging from ($1.43) to ($0.72). Wave Life Sciences posted earnings per share of ($1.26) in the same quarter last year, which indicates a positive year-over-year growth rate of 5.6%. The company is scheduled to report its next quarterly earnings report on Wednesday, May 8th.

According to Zacks, analysts expect that Wave Life Sciences will report full year earnings of ($3.91) per share for the current financial year, with EPS estimates ranging from ($5.82) to ($1.78). For the next fiscal year, analysts forecast that the business will post earnings of ($4.98) per share, with EPS estimates ranging from ($6.14) to ($3.60). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that that provide coverage for Wave Life Sciences.

Wave Life Sciences (NASDAQ:WVE) last issued its quarterly earnings data on Friday, March 1st. The company reported ($1.29) earnings per share for the quarter, missing the consensus estimate of ($1.24) by ($0.05). Wave Life Sciences had a negative net margin of 1,017.43% and a negative return on equity of 136.64%. The company had revenue of $3.62 million for the quarter, compared to the consensus estimate of $6.01 million.

Several brokerages recently weighed in on WVE. Mizuho reaffirmed a “buy” rating and issued a $65.00 price target on shares of Wave Life Sciences in a research note on Monday. BidaskClub raised Wave Life Sciences from a “sell” rating to a “hold” rating in a report on Wednesday, April 10th. ValuEngine downgraded Wave Life Sciences from a “strong-buy” rating to a “buy” rating in a report on Monday, March 25th. Finally, Zacks Investment Research downgraded Wave Life Sciences from a “hold” rating to a “sell” rating in a report on Saturday, March 9th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $57.75.

In other Wave Life Sciences news, Director Ra Capital Management, Llc purchased 263,158 shares of the stock in a transaction dated Thursday, January 24th. The shares were purchased at an average cost of $38.00 per share, with a total value of $10,000,004.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Paul Bolno sold 50,000 shares of the stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $45.48, for a total value of $2,274,000.00. The disclosure for this sale can be found here. Corporate insiders own 44.20% of the company’s stock.

A number of hedge funds have recently bought and sold shares of the business. BlackRock Inc. lifted its holdings in Wave Life Sciences by 27.8% in the fourth quarter. BlackRock Inc. now owns 1,552,595 shares of the company’s stock valued at $65,273,000 after acquiring an additional 337,752 shares during the period. BB Biotech AG raised its stake in shares of Wave Life Sciences by 5.8% in the fourth quarter. BB Biotech AG now owns 1,465,002 shares of the company’s stock worth $61,589,000 after buying an additional 80,000 shares during the period. Point72 Asset Management L.P. raised its stake in shares of Wave Life Sciences by 14.3% in the third quarter. Point72 Asset Management L.P. now owns 400,000 shares of the company’s stock worth $20,000,000 after buying an additional 50,000 shares during the period. Vanguard Group Inc raised its stake in shares of Wave Life Sciences by 5.7% in the third quarter. Vanguard Group Inc now owns 309,765 shares of the company’s stock worth $15,488,000 after buying an additional 16,794 shares during the period. Finally, Vanguard Group Inc. raised its stake in shares of Wave Life Sciences by 5.7% in the third quarter. Vanguard Group Inc. now owns 309,765 shares of the company’s stock worth $15,488,000 after buying an additional 16,794 shares during the period. 71.31% of the stock is currently owned by institutional investors.

NASDAQ:WVE traded down $0.06 during mid-day trading on Monday, reaching $34.02. The stock had a trading volume of 532,875 shares, compared to its average volume of 399,168. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.56 and a quick ratio of 1.56. Wave Life Sciences has a one year low of $32.25 and a one year high of $56.00. The company has a market capitalization of $1.16 billion, a price-to-earnings ratio of -6.72 and a beta of 0.83.

Wave Life Sciences Company Profile

Wave Life Sciences Ltd., a biotechnology company, designs, develops, and commercializes nucleic acid therapeutic candidates for genetically defined diseases by utilizing proprietary synthetic chemistry drug development platform. The company is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.

Featured Article: Front-End Load

Get a free copy of the Zacks research report on Wave Life Sciences (WVE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Wave Life Sciences (NASDAQ:WVE)

Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.